

**Congress of the United States**  
**House of Representatives**  
Washington, DC 20515

December 22, 2014

Tom Frieden, MD, MPH  
Director  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, Georgia 30329-4027

RE: Solicitation # 2014-N-16818

Dear Dr. Frieden,

We write to you on behalf of Protein Sciences Corporation headquartered in Meriden, Connecticut. As you know, Protein Sciences specializes in vaccine development and protein production.

Through their proprietary BEVS protein expression technology, they developed Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease. Flublok was approved by FDA in January 2013. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus or antibiotics in manufacturing. Flublok is highly purified and does not contain any preservatives, egg proteins, gelatin or latex. In addition, Flublok contains three times more antigen than traditional flu vaccines.

In light of the CDC's recent warning that flu vaccines might be ineffective this season given that the newest strain, H3N2, was not included, we are asking the CDC to consider purchasing the 250,000 doses offered by Protein Sciences through their response to Solicitation # 2014-N-16818. Protein Sciences maintains that because Flublok "contains 3x more antigen than traditional trivalent flu vaccines and induces a stronger antibody response against the influenza A viruses" it is expected that Flublok would be more effective with the H3N2 virus as it is an influenza A virus.


We have worked with Protein Sciences Corporation on a variety of issues and have always been impressed with the dedication and resolve that the company and its leadership have demonstrated in their innovative approach to vaccine development. Protein Sciences is at the forefront of technological advancements in their field. Flublok is the only the only flu vaccine made in America by an American company and only flu vaccine recommended by the Advisory Committee on Immunization Practices (ACIP) for people who have known or suspected egg allergies, regardless of severity.

We believe that upon review of their submission as well as the Flublok product itself, you will find that this product may best serve the CDC's mission during the 2015-2016 flu season. We urge you to give their proposal every possible consideration. Thank you for your time and attention to our comments.

Sincerely,



ROSA L. DeLAURO  
Member of Congress



ELIZABETH H. ESTY  
Member of Congress